Christopher Yea - 27 May 2026 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Reporting relationship: CHIEF DEVELOPMENT OFFICER
Issuer ticker: KALV
Reported as of: 27 May 2026
Net transaction value: -$905,225
SEC form: 4
Accepted by SEC: 29 May 2026, 16:05:10 UTC
Prior SEC filing: 27 May 2026
Next SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact

Key filing fact

Christopher Yea filed Form 4 for KalVista Pharmaceuticals, Inc. (KALV) on 29 May 2026.

Key facts

This page summarizes Christopher Yea's Form 4 filing for KalVista Pharmaceuticals, Inc. (KALV).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 May 2026, 16:05.

Change

Previous filing in this sequence was filed on 27 May 2026.
Current net transaction value: -$905,225.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001691102 Primary reporting owner

Yea Christopher

Relationship: CHIEF DEVELOPMENT OFFICER
Address: C/O KALVISTA PHARMACEUTICALS, INC., 200 CROSSING BOULEVARD, FRAMINGHAM
Signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact
Signature date: 29 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KALV transaction

Common Stock

Options Exercise

Transaction value
Shares: +33,800
Change %: +15%
Price: $7.07^*
Shares after: 263,718
Date: 27 May 2026
Ownership: Direct

KALV transaction

Common Stock

Sale

Transaction value: $905,225
Shares: -33,800
Change %: -13%
Price: $26.78
Shares after: 229,918
Date: 27 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KALV transaction Derivative

Employee Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -33,800
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,800
Exercise price: $7.07
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.78 to $26.79 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F2

This option is 100% vested and exercised.